Telescope Innovations Corp. (TELIF)
USD 0.24
(-13.04%)
USD 0.24
(-13.04%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.54 Million CAD | -44.24% |
| 2022 | 6.35 Million CAD | 57.88% |
| 2021 | 4.02 Million CAD | 1490.5% |
| 2020 | 252.97 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.23 Million CAD | 23.47% |
| 2023 Q2 | 808.71 Thousand CAD | 1.86% |
| 2023 Q1 | 793.98 Thousand CAD | -41.33% |
| 2023 FY | 3.54 Million CAD | -44.24% |
| 2023 Q4 | 1 Million CAD | 6.82% |
| 2023 Q3 | 937.8 Thousand CAD | 15.96% |
| 2022 Q4 | 1.35 Million CAD | 36.67% |
| 2022 Q3 | 990.19 Thousand CAD | -69.21% |
| 2022 Q2 | 3.21 Million CAD | 305.95% |
| 2022 Q1 | 792.32 Thousand CAD | 43.13% |
| 2022 FY | 6.35 Million CAD | 57.88% |
| 2021 Q3 | 3.29 Million CAD | 9880.67% |
| 2021 FY | 4.02 Million CAD | 1490.5% |
| 2021 Q4 | 553.56 Thousand CAD | -83.2% |
| 2021 Q2 | 33.01 Thousand CAD | -13.59% |
| 2021 Q1 | 38.21 Thousand CAD | 15.63% |
| 2020 Q4 | 33.04 Thousand CAD | 0.0% |
| 2020 Q2 | 33.06 Thousand CAD | 0.0% |
| 2020 FY | 252.97 Thousand CAD | 0.0% |
| 2019 Q4 | 33.24 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ContraFect Corporation | 56.88 Million USD | 93.773% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -20233.207% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 14268.992% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -164.042% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 95.918% |
| Kadimastem Ltd | 2.41 Million USD | -46.974% |
| Zenith Capital Corp. | 8.94 Million USD | 60.391% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -89.997% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -13973.853% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 47.272% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1253.418% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -139.543% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 90.492% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -135.851% |
| Qrons Inc. | 643.67 Thousand USD | -450.315% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -124.284% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -44.268% |
| Accustem Sciences Inc. | 3.74 Million USD | 5.45% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -565.884% |
| Affymax, Inc. | 39.38 Million USD | 91.006% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.434% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 29.746% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -26.946% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -165.251% |
| Biomind Labs Inc. | 994.18 Thousand USD | -256.298% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 67.404% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -34.813% |
| CytoDyn Inc. | 18.05 Million USD | 80.384% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 88.014% |
| IMV Inc. | 37.7 Million USD | 90.606% |
| Genus plc | 147.7 Million USD | 97.602% |
| Halberd Corporation | 74.84 Thousand USD | -4632.968% |
| Helix BioMedix, Inc. | 1.97 Million USD | -79.624% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 27.973% |
| LadRx Corporation | 3.81 Million USD | 7.071% |
| Marizyme, Inc. | 19.23 Million USD | 81.589% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1509.542% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 85.668% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 19.653% |
| Q BioMed Inc. | 3.43 Million USD | -3.073% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -283.564% |
| Enzolytics Inc. | 2.17 Million USD | -62.525% |
| CSL Limited | 3.44 Billion USD | 99.897% |
| Skye Bioscience, Inc. | 13.54 Million USD | 73.853% |
| SQZ Biotechnologies Company | 85.61 Million USD | 95.863% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -72.902% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 59.652% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1965.342% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -47.291% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -239.296% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 57.522% |
| NovAccess Global Inc. | 2.46 Million USD | -43.599% |
| HST Global, Inc. | 140.9 Thousand USD | -2413.891% |
| SYBLEU INC | 160.87 Thousand USD | -2101.85% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 95.878% |
| Alpha Cognition Inc. | 9.7 Million USD | 63.503% |
| AVAX Technologies, Inc. | 7.31 Million USD | 51.544% |
| Mesoblast Limited | 5.9 Million USD | 39.982% |
| MultiCell Technologies, Inc. | 567.42 USD | -624172.673% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -21.466% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 77.875% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -809.281% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 98.429% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -93.028% |
| GB Sciences, Inc. | 1.42 Million USD | -149.365% |
| argenx SE | 1.53 Billion USD | 99.769% |
| Resverlogix Corp. | 12.71 Million USD | 72.135% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 2.971% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 93.833% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -101.301% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -4.031% |
| ONE Bio Corp. | 6.44 Million USD | 45.029% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.571% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -84.405% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -214.892% |
| Agentix Corp. | 1.37 Million USD | -158.227% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 84.582% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1851.813% |
| Cell Source, Inc. | 4.32 Million USD | 18.105% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -752.57% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -283.564% |
| Itoco Inc. | 919.14 Thousand USD | -285.386% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 16.425% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -216.555% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -149.491% |
| Nascent Biotech, Inc. | 2.22 Million USD | -58.854% |
| Rebus Holdings, Inc. | 664 Thousand USD | -433.471% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -95.023% |
| Mobile Lads Corp. | 554.54 Thousand USD | -538.765% |
| International Stem Cell Corporation | 5.27 Million USD | 32.797% |
| Bioxytran, Inc. | 3.82 Million USD | 7.275% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -6628.939% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -17312.614% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 90.233% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -118.928% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -381.392% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -13.862% |
| Neutra Corp. | 243.82 Thousand USD | -1352.807% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 79.709% |
| PureTech Health plc | 144.59 Million USD | 97.55% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 82.712% |
| IXICO plc | 4.7 Million USD | 24.745% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 59.733% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 96.992% |
| CSL Limited | 3.89 Billion USD | 99.909% |
| Cellectis S.A. | 97.32 Million USD | 96.36% |